bi 754111
mAbexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 13, 2017 (NCT03156114)
Timeline
Indications
Mechanism of action
- Lymphocyte activation gene 3 proteinINHIBITOR
LAG3 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- bi 754111
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03964233 | Phase 1 | Jun 11, 2019 | Boehringer Ingelheim |
| NCT03697304 | Phase 2 | Mar 7, 2019 | Boehringer Ingelheim |
| NCT03780725 | Phase 1 | Jan 22, 2019 | Boehringer Ingelheim |
| NCT03433898 | Early Phase 1 (Phase 1) | Feb 23, 2018 | Boehringer Ingelheim |
| NCT03156114 | Phase 1 | Jun 13, 2017 | Boehringer Ingelheim |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 5 | 5 | 2 | 2017 |
1 organizations
Page 1 / 1